Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687359 · ClinicalTrials.gov registry record
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
A clinical trial of Dermatitis, Atopic, sponsored by Sanofi.
- Active
- Registry status
- 1,860
- Enrollment target
- 20
- Study locations
NCT03687359: Active study of Dermatitis, Atopic, sponsored by Sanofi.
NCT03687359 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 1,860 participants, above the 333-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (459% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03687359, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 1,860 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.
Conditions Studied
Interventions
- OTHER Standard of care
Study Locations (20)
Florida
- Daxia Trials- Site Number : 8400082 - Boca Raton
- Frieder Dermatology- Site Number : 8400085 - Boca Raton
- Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology, LLC- Site Number : 8400072 - Coral Gables
- Green Dermatology and Cosmetic Center. Site Number : 8400078 - Deerfield Beach
- Amedica Research Institute, Inc.- Site Number : 8400067 - Hialeah
- Eastern Research, Inc.- Site Number : 8400032 - Hialeah
- Premier Dermatology Partners- Site Number : 8400075 - Miami
- Nicklaus Children's Hospital - Miami - Southwest 62nd Avenue- Site Number : 8400074 - Miami
- Vista Health Research, LLC- Site Number : 8400034 - Miami
- Pediatric & Adult Research Center- Site Number : 8400040 - Orlando
- Elias Dermatology LLC- Site Number : 8400086 - Pembroke Pines
- Elias Dermatology LLC- Site Number : 8400087 - Pembroke Pines
California
- Orange County Research Institute- Site Number : 8400028 - Anaheim
- Axis Clinical Trials- Site Number : 8400025 - Los Angeles
- Madera Family Medical Group- Site Number : 8400054 - Madera
- Carey Chronis, MD, FAAP- Site Number : 8400033 - Ventura
Alabama
- C Squared Research Center- Site Number : 8400068 - Birmingham
- Cahaba Dermatology & Skin Health Center- Site Number : 8400046 - Birmingham
- C2 Research Center, LLC- Site Number : 8400071 - Montgomery
Arizona
- Phoenix Children's Hospital, Inc.- Site Number : 8400015 - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,860 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2035-07-23 |
What the registry record for NCT03687359 still lists
NCT03687359 is an observational study that tracks outcomes without assigning an intervention. Its 1,860 participants enrollment target places it among the larger protocols in the corpus, above the 333-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (459% higher).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Standard of care is the first listed.
NCT03687359 names 20 study sites across 4 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03687359 about?
NCT03687359 is a clinical study titled "Observational Evaluation of Atopic Dermatitis in Pediatric Patients". Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic c...
What is the current status of trial NCT03687359?
This trial is currently active not recruiting. The enrollment target is 1,860 participants. The study started on 2019-08-15. Estimated completion is 2035-07-23.
What conditions does trial NCT03687359 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03687359?
The interventions under investigation include: Standard of care (OTHER).
Who is sponsoring clinical trial NCT03687359?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03687359 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03687359's enrollment target sits among peer trials
1,860 1st of 29 higher than 29 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI